u/ferran_mensah

Correction: patient-specific refers to the prescription, not to a bespoke formulation. Common misreading and it changes the argument.

Perimenopausal, or is that a separate question?

Careful — anything touching pregnancy is not a board question in any form.

Personal importation provisions exist, are narrow, and carry conditions. Any summary of them here should be checked against the current official wording rather than a forum post.

Agreed. The 503A versus 503B distinction changes who is allowed to make what, and almost every confused thread here starts by ignoring it.

Small fix — 503B facilities register with the regulator; 503A pharmacies are licensed by the state board. Different mechanisms.

Have you held a step for longer than the four-week minimum at any point?

Correction to my own post above — I said 10mg and I have been on 12.5mg since the spring. Same argument, wrong number.

2.5mg is a four-week starting dose, not a maintenance dose. Worth being precise since people search these threads.

The distribution matters more than the mean. In the trial population the interquartile spread was wide enough that two honest people can have completely different runs on the same arm.

That is not what patient-specific means. It refers to the prescription, not to a customisation of the formula.

symptom patterns can track the cycle rather than the dose

Research-use-only material is not approved for human use. Anything in this thread about how a research vial "should" titrate is a discussion about chemistry, not a plan.

Disagree with the conversion table. There is no validated equivalence between the two molecules and posting one as though there is does real damage.

Appetite effect for me is flat across seven days. On sema it was a wave. Same person, different molecule.

Supply notices from the regulator describe expected availability at a national level. They do not predict what any individual pharmacy has on the shelf next week.

Registration by the therapeutic goods regulator establishes that a product may be supplied. Subsidy listing is a separate decision about public funding, with its own criteria and its own timetable.

switching from sema is not a dose conversion, there is no clean equivalence

Gently disagree with the framing — that is not a plateau, that is a month. They are different things.

the timeframe matters as much as the number

Came off sema and onto tirz with a two-week gap. The first month was flat and I assumed I had made a mistake. Month two it moved.

Hormonal variation across the cycle affects appetite, fluid retention and subjective symptom intensity independently of anything else, which is why an unannotated log can look mysterious.

That percentage is body weight change, not body fat. Different measurement, and the distinction gets lost every time.

2.5 is the starter dose and it is not meant to be the dose that works

the label on a compounded vial is a legal document, read it

Are you logging the cycle alongside the dose?

This is the practical fix for half the confusing weeks on this board — annotate the cycle.

GP said no and specialist said yes is a very common sequence

GP said no in the spring, specialist said yes eighteen months later. Same person, same numbers.

compounded is not generic, there is no equivalence claim

Australia and New Zealand have different regulators, different funding bodies and different arrangements. An answer for one is not evidence about the other.

Nothing on this board is medical advice, and rate, target and method are questions for somebody who knows your history.

This. Compounded preparations carry no equivalence claim, and treating them as generics is a category error people make constantly.

Push back: PCOS as a diagnosis and insulin resistance as a finding are not interchangeable, and the thread is using them as one.

no referral links, ever, and that rule is why the pricing threads work

ask which facility, then ask for their testing

Pharmacy-level availability and national supply are different questions: a pharmacy can be out while the wholesaler is not, and the pharmacist can check in minutes.

ask what the beyond-use date is based on

Correction: that threshold is your ICB’s, not a national one. They differ and they change by year.

Four pharmacies, four prices, same product, same month. The spread was larger than I expected and none of them were the headline offer.

That figure is the starting material purity, not the finished preparation potency. Two different tests.